معرفی
Brent Page is an Associate Professor (tenured) in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) and maintains a research group at the Karolinska Institute, Department of Oncology and Pathology. His dual affiliation underpins a trans-Atlantic program that integrates cutting-edge chemical biology with medicinal chemistry for anti-cancer drug discovery.
Education & Training
- PhD in Chemistry – University of Toronto (2013)
- HBSc in Chemistry (Honours) – University of British Columbia (2008)
- CIHR Postdoctoral Fellow – Karolinska Institute, Sweden (2008–2016)
- Assistant Professor (non-independent) – Karolinska Institute, Department of Oncology-Pathology (2017–2021)
Research Focus
Dr. Page’s laboratory operates at the interface of medicinal chemistry and chemical biology, aiming to identify and optimize small-molecule inhibitors for proteins previously considered “undruggable.” Core targets include STAT3, CLIC3, NUDT5/15 and SRPK3. The group employs cellular thermal shift assays, isothermal ligand-induced resolubilization (ILIRA), and CeTEAM technologies to quantify target engagement and refine structure–activity relationships in physiologically relevant models of breast cancer, triple-negative breast cancer, leukemia and atopic diseases.
Funding & Collaborations
His program is supported by Canadian Institutes of Health Research (CIHR) and other national and international agencies. Dr. Page actively participates in UBC’s Accelerated Translational Opioid Research Cluster and welcomes interdisciplinary collaborations and undergraduate research involvement.
Equity, Diversity & Inclusion
Committed to fostering an inclusive environment, Dr. Page mandates EDI training for all lab members and actively encourages participation from equity-deserving groups.
